Research Associate - Scientific Services

Altasciences expands bioanalytical labs in North america. New and expanded facilities will support rising demand for late-stage clinical bioanalysis. August 11, 2026 Associate Editor Editor's Take: Global pharmaceutical companies continue to pour hundreds of billions of dollars into U.S. manufacturing, R&D and supply chain infrastructure to localize production and bolster domestic capacity. Altasciences is expanding its North American bioanalytical laboratory footprint with a 4,000-square-foot addition to the company's laboratory in Greater Montréal and a new 13,000-square-foot purpose-built laboratory in Harleysville, Pennsylvania. The lab in Canada is expected to be fully operational by the end of Q3 2026, while construction on the Pennsylvania site will proceed in phases, with Phase 1 scheduled for completion in Q1 2027. These investments significantly increase Altasciences' ability to support the growing demand for late-stage clinical bioanalysis while providing sponsors with greater flexibility, scalability, and operational resilience. Supporting demand for sophisticated bioanalytical support. Designed to support increasingly complex development programs, the expanded laboratories will result in increased capacity to conduct larger studies and higher sample volumes while incorporating "state-of-the-art" instrumentation and advanced laboratory automation for pharmacokinetic and pharmacodynamic assay method development, validation, and sample analysis across the clinical phases of drug development. "Our clients are bringing increasingly complex molecules into development, and that is driving unprecedented demand for sophisticated bioanalytical support," said Lynne Le Sauteur, Vice President, Laboratory Sciences, Altasciences. "We're investing ahead of that demand by expanding capacity where sponsors need it most and deploying state-of-the-art instrumentation and automation that enhances speed without compromising quality." The expansion project strengthens Altasciences' broader North American bioanalytical network, which includes established laboratories in Greater Montréal (Quebec), Seattle (Washington), and Columbia (Missouri). Together, these locations provide sponsors with bioanalytical expertise and capacity across the drug development continuum. Meanwhile, network-wide harmonization enables sponsors to leverage capacity across locations, transition work seamlessly between laboratories, and maintain complete confidence in the integrity and consistency of their bioanalytical data. "This investment is about far more than expanding laboratory space," said Robert Sabelli, Co-Chief Operating Officer, Altasciences. "We're building one of the industry's most integrated and scalable bioanalytical networks. As clinical programs become larger, more complex, and increasingly global, sponsors need a partner that can rapidly scale capacity while delivering consistent scientific excellence across every location. That's exactly what we're delivering."

Altasciences completes expansion of research and development laboratory in Harleysville, Pennsylvania. Business Wire Published Aug 04, 2026 Article content LAVAL, Québec - Altasciences is excited to share it has expanded the R&D laboratory at its drug product formulation and manufacturing services facility in Harleysville, Pennsylvania, adding approximately 768 square feet of new laboratory space. Article content With this expansion, we are strengthening our focus on early-stage integration, bringing our CDMO capabilities to clients earlier in the drug development journey. Article content The expansion brings together formulation development and analytical testing within a single laboratory. This integrated setup is designed to accelerate decision-making, streamline workflows, and strengthen collaboration across scientific disciplines. Article content Advertisement 1 Story continues below This advertisement has not loaded yet, but your article continues below. Article content "With this expansion, we are strengthening our focus on early-stage integration, bringing our CDMO capabilities to clients earlier in the drug development journey," said Anuji Abraham, Senior Director, Pharmaceutical Development, CDMO Services, Altasciences. "This enhances continuity across nonclinical and clinical programs, helping clients navigate key development milestones more efficiently and effectively." Article content Top Stories Interested in more newsletters? Browse here. Article content The enhanced laboratory supports phase-appropriate, target product profile (TPP)-driven formulation screening, tailored to both therapeutic areas and routes of administration while remaining agnostic to both. Capabilities include formulation development for small molecules, peptides, and complex modalities, as well as non-GLP and GLP toxicology samples for nonclinical studies. Article content Advanced screening models and integrated analytical testing support nonclinical and clinical readiness, in addition to real-time formulation decisions. By operating in a non-GLP R&D environment, clients will gain flexibility to design and optimize their products before transitioning into regulated studies. Article content "This expansion is not just about building additional space," said Robert Sabelli, Co-Chief Operating Officer, Altasciences. "By continuing to invest in our team, we are growing our scientific talent and connecting our capabilities earlier in the development cycle to better support our clients - and ultimately, the patients they serve." Article content About Altasciences Article content is a drug development organization dedicated to safely accelerating early-phase development for biotech, biopharmaceutical, and pharmaceutical companies. By combining the scale and expertise of a large CRO/CDMO with the flexibility and personalized approach of a mid-size partner, Altasciences delivers unified solutions across Article content , and formulation, and Article content . Through intentional integration and true collaboration, the company removes barriers from lead candidate selection to clinical proof-of-concept - helping sponsors save time, reduce complexity, and make confident, data-driven decisions that enable earlier returns on investment. Guided by over 30 years of experience and a commitment to quality, integrity, and partnership, Altasciences enables clients to reach critical milestones faster and with greater confidence. To learn more about Altasciences, visit Article content View source version on businesswire.com: Article content Advertisement 1 This advertisement has not loaded yet.